15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Context Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $4.00 to $9.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $6.17 sits 1556% above the current $0.37. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Context Therapeutics Inc.
As of Sep, 7 of 7 firms rate CNTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CNTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.17 – $-0.08 · 8 analysts · -19% YoY
Next period, 8 analysts expect Context Therapeutics Inc to earn $-0.11 a share (range $-0.17 – $-0.08), versus $-0.14 a year earlier. Full-year consensus is $-0.46, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Context Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CNTX.
#1
Silvan Tuerkcan
JMP Securities · Rank #26
Buy
$4.00+974.4% to target
Overall win rate
53%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #275
Buy
No targeton CNTX
Overall win rate
36%
+ Follow
#3
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$5.00+1243.0% to target
Overall win rate
23%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #416
Buy
$9.00+2317.4% to target
Overall win rate
22%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #428
Buy
$4.00+974.4% to target
Overall win rate
32%
+ Follow
CNTX stock forecast FAQ
What is CNTX's average 12-month price target?+
The 6 analysts with a live target average $6.17 for Context Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $4.00 low.
Is CNTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CNTX?+
The Street-high target is $9.00 (D. Boral Capital), and the Street-low is $4.00 (Maxim Group). The average of all 6 active targets is $6.17.
How many Wall Street analysts cover CNTX?+
7 analysts have an active rating on Context Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CNTX?+
Among analysts who currently cover CNTX, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #26). Their current call is Buy with a $4.00 target.
What is Context Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.17 – $-0.08) across 8 analysts. Full-year EPS is projected at $-0.46, rising to $-0.44 the following year.
How much revenue is Context Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CNTX lately?+
As of Sep, 7 of 7 firms rate CNTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CNTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
